20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
- Putting all the speculations at bay, Merck & Co Inc (NYSE:MRK) has agreed to acquire Acceleron Pharma Inc (NASDAQ:XLRN) for $180 per share in cash for an approximate total equity value of $11.5 billion.
- Related Link: Merck Reportedly Lead Bidder In $11B Acceleron Buyout: WSJ.
- Acceleron's lead therapeutic candidate, sotatercept, has a novel mechanism of action with the potential to improve short-term and/or long-term clinical outcomes in patients with pulmonary arterial hypertension (PAH).
- Sotatercept is in Phase 3 trials as an add-on to the current standard of care for treating PAH.
- In addition to sotatercept, Acceleron's portfolio includes Reblozyl (luspatercept-aamt), an erythroid maturation recombinant fusion protein approved for anemia in certain rare blood disorders.
- Reblozyl is being developed and commercialized through global collaboration with Bristol Myers Squibb & Co (NYSE:BMY).
- Related: Bristol-Myers, Acceleron's Reblozyl Ok'd In Canada For MDS-Associated Anemia.
- The transaction is expected to close in Q4 of 2021.
- Price Action: XLRN stock is up 0.56% at $176.35, MRK shares are up 0.87% at $75.74 during the premarket session on the last check Thursday.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!